

WHAT IS CLAIMED IS:

1. A composition, comprising at least 3 CTL peptides in Table 3 (SEQ ID NOs:2-10).
2. The composition of claim 1, which comprises at least 4 CTL peptides in Table 3 (SEQ ID NOs:2-10).
3. The composition of claim 1, which comprises at least 5 CTL peptides in Table 3 (SEQ ID NOs:2-10).
4. The composition of claim 1, which comprises at least 6 CTL peptides in Table 3 (SEQ ID NOs:2-10).
5. The composition of claim 1, which comprises at least 7 CTL peptides in Table 3 (SEQ ID NOs:2-10).
6. The composition of claim 1, which comprises at least 8 CTL peptides in Table 3 (SEQ ID NOs:2-10).
7. The composition of claim 1, which comprises all 9 CTL peptides in Table 3 (SEQ ID NOs:2-10).
8. The composition of any of claims 1-7, which further comprises an HTL peptide.
9. The composition of claim 8, wherein said HTL peptide comprises SEQ ID NO:1.
10. The composition of any of claims 1-9, which further comprises one or more diluents, different CTL epitopes, different HTL epitopes, carriers, liposomes, an HLA heavy chain, β 2-microglobulin, streptavidin, antigen-presenting cell, and/or an adjuvant.
11. The composition of claim 10, which further comprises an adjuvant.
12. The composition of claim 11, wherein said adjuvant is a mineral oil adjuvant.
13. A method of delaying the recurrence of cancer following surgery, chemotherapy or radiation comprising administering the composition of any one of claims 1-12 to a patient.
14. The method of claim 13, wherein said cancer is selected from the group consisting of:
 - a. colon cancer;
 - b. non-small cell lung cancer (NSCLC);
 - c. breast cancer;
 - d. ovarian cancer; and
 - e. a cancer of the head and/or neck.